![]() |
Volumn 86, Issue 11, 2002, Pages 1667-1669
|
Why hasn't the National Institute been 'NICE' to patients with colorectal cancer?
a
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
RALTITREXED;
ALOPECIA;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL TRIAL;
COLORECTAL CARCINOMA;
COST EFFECTIVENESS ANALYSIS;
DIARRHEA;
DRUG CHOICE;
DRUG EFFICACY;
DRUG INDICATION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
EDITORIAL;
HEALTH CARE COST;
HUMAN;
PRACTICE GUIDELINE;
PRIMARY HEALTH CARE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SURVIVAL RATE;
ANTINEOPLASTIC AGENTS;
ATTITUDE TO HEALTH;
COLORECTAL NEOPLASMS;
CROSS-OVER STUDIES;
GOVERNMENT AGENCIES;
GREAT BRITAIN;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
|
EID: 0037024432
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bjc.6600369 Document Type: Editorial |
Times cited : (8)
|
References (13)
|